X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (25) 25
female (21) 21
oncology (21) 21
middle aged (20) 20
index medicus (19) 19
male (19) 19
aged (17) 17
adult (12) 12
aged, 80 and over (11) 11
cancer (11) 11
chemotherapy (11) 11
treatment outcome (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
neoplasms - drug therapy (8) 8
care and treatment (7) 7
tumors (7) 7
cancer therapies (6) 6
double-blind (6) 6
efficacy (6) 6
medicine & public health (6) 6
patients (6) 6
research (6) 6
vomiting (6) 6
antineoplastic agents - therapeutic use (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
chemotherapy-induced nausea and vomiting (5) 5
clinical trials (5) 5
disease-free survival (5) 5
double-blind method (5) 5
nausea (5) 5
dose-response relationship, drug (4) 4
drug administration schedule (4) 4
drug dosages (4) 4
health care sciences & services (4) 4
hematology (4) 4
metastasis (4) 4
palonosetron (4) 4
pharmacology & pharmacy (4) 4
prevention (4) 4
prognosis (4) 4
severity of illness index (4) 4
survival (4) 4
time factors (4) 4
anthracycline (3) 3
antineoplastic agents - adverse effects (3) 3
apf530 (3) 3
breast cancer (3) 3
cancer patients (3) 3
cohort studies (3) 3
combination (3) 3
docetaxel (3) 3
drug therapy (3) 3
fatigue (3) 3
further section (3) 3
granisetron (3) 3
immunotherapy (3) 3
multicenter (3) 3
multiple myeloma - drug therapy (3) 3
nausea - chemically induced (3) 3
neoplasms - complications (3) 3
pharmacokinetics (3) 3
prospective studies (3) 3
quality-of-life (3) 3
safety (3) 3
solid tumors (3) 3
therapy (3) 3
adolescent (2) 2
american society (2) 2
anemia - chemically induced (2) 2
antiemetics (2) 2
antimetabolites, antineoplastic - administration & dosage (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - pharmacokinetics (2) 2
apoptosis (2) 2
article (2) 2
boronic acids - therapeutic use (2) 2
bortezomib (2) 2
breast neoplasms - drug therapy (2) 2
cancer research (2) 2
combined modality therapy (2) 2
comparative analysis (2) 2
complications and side effects (2) 2
crm1 (2) 2
cross-over studies (2) 2
delayed-action preparations (2) 2
development and progression (2) 2
diarrhea - chemically induced (2) 2
dosage and administration (2) 2
fda approval (2) 2
fluorouracil - administration & dosage (2) 2
gemcitabine (2) 2
gene expression (2) 2
halichondrin b (2) 2
hematology, oncology and palliative medicine (2) 2
highly emetogenic chemotherapy (2) 2
hydrazines - administration & dosage (2) 2
identification (2) 2
injections, subcutaneous (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Cancer Research, ISSN 1078-0432, 01/2019, Volume 25, Issue 2, pp. 496 - 505
Purpose: This study examined safety, pharmacokinetics, and efficacy of veliparib, a PARP inhibitor, combined with carboplatin and etoposide in patients with... 
TRIAL | SINGLE-AGENT | GERMLINE BRCA1 | ABT-888 | PLUS CARBOPLATIN | OVARIAN-CANCER | DNA-REPAIR | COMBINATION | CHEMOTHERAPY | PARP INHIBITOR VELIPARIB | ONCOLOGY | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. TPS9593 - TPS9593
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 3966 - 3966
Abstract Introduction: Pralatrexate is a folate analogue indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) that is... 
Journal Article
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, ISSN 2042-6305, 07/2019, Volume 8, Issue 9, pp. 657 - 670
Aim: To evaluate real-world effectiveness of guideline-recommended palonosetron-containing antiemetic regimens in patients receiving highly (HEC) or moderately... 
EFFICACY | SAFETY | CONSENSUS RECOMMENDATIONS PREVENTION | APF530 | RESOURCE UTILIZATION | granisetron extended-release sc | IMPACT | RELEASE GRANISETRON | MODERATELY EMETOGENIC CHEMOTHERAPY | HEALTH CARE SCIENCES & SERVICES | palonosetron | QUALITY-OF-LIFE | chemotherapy-induced nausea and vomiting | AMERICAN SOCIETY
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 3040 - 3040
Abstract Histone deacetylase (HDAC) enzymes are attractive therapeutic targets in oncology, but non-selective HDAC inhibitors have led to dose-limiting... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 258 - 258
Abstract Background: The nuclear export protein XPO1 is overexpressed in all types of hematological malignancies. The SINE selinexor (KPT-330) is a novel,... 
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 4047 - 4047
Abstract Background We previously reported that patients with MF enrolled in a randomized Phase II study of fedratinib (SAR302503) (ARD11936; NCT01420770) had... 
Journal Article
Blood, ISSN 0006-4971, 11/2012, Volume 120, Issue 21, pp. 2837 - 2837
Abstract Abstract 2837 Introduction: Treatment with the JAK2 selective inhibitor SAR302503 reduced spleen size, disease-related symptoms, and the JAK2 V617F... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2013, Volume 31, Issue 35, pp. 4400 - 4406
Journal Article
Blood, ISSN 0006-4971, 11/2011, Volume 118, Issue 21, pp. 3480 - 3480
Abstract Abstract 3480 Background: The recommended starting dose for all patients receiving SC AZA is 75 mg/m2 daily for 7 days in 28-day cycles. If no... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.